Genmab A (GMAB) Interest Expenses (2019 - 2026)
Genmab A's (GMAB) quarterly Interest Expenses came in at -$150.0 million in Q1 2026, down 233.33% YoY from $112.5 million in Q1 2025, and up 11.76% on a QoQ basis from -$170.0 million in Q3 2025.
Genmab A (GMAB) Interest Expenses (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Interest Expenses data on file, last reported at -$150.0 million in Q1 2026.
- Quarterly Interest Expenses fell 233.33% year-over-year to -$150.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$186.0 million (down 20.0% YoY) and the FY2025 annual result came in at $269.0 million, down 7.56% from the prior year.
- Interest Expenses improved to -$150.0 million in Q1 2026, from -$170.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $134.0 million in Q2 2025 to a low of -$181.0 million in Q3 2024.
- A 4-year average of -$43.3 million and a median of -$35.0 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2025 — Interest Expenses soared 67.5% — and 2026, when it sank 233.33%.
- Tracing GMAB's Interest Expenses over 4 years: stood at -$14.0 million in 2023, then jumped by 35.71% to -$9.0 million in 2024, then sank by 1788.89% to -$170.0 million in 2025, then grew by 11.76% to -$150.0 million in 2026.
- The last three Interest Expenses figures came in at -$150.0 million (Q1 2026), -$170.0 million (Q3 2025), and $134.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 139.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139.00 Mn |
| Jun 30, 2026 | 139.00 Mn |
| Mar 31, 2026 | -150.00 Mn |
| Mar 31, 2026 | -150.00 Mn |
| Sep 30, 2025 | -170.00 Mn |
| Sep 30, 2025 | -170.00 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Mar 31, 2025 | -45.00 Mn |
| Mar 31, 2025 | -45.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Jun 30, 2024 | 80.00 Mn |
| Jun 30, 2024 | 80.00 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Dec 31, 2023 | -14.00 Mn |
| Dec 31, 2023 | -14.00 Mn |